Interesting Article from MDLinx

MDLinx  Psychiatry

5 minutes to stay current

Your Article Summary

Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: A randomized double blind placebo controlled clinical trial
Journal of Affective Disorders, 07/31/14
Sahraian A, et al. – The authors examined whether obsessive compulsive symptoms in patients with bipolar disorder respond to topiramate as an adjuvant treatment. They found that the combination of lithium+olanzapine+clonazepam decreased the symptoms of obsessive compulsive disorder in the patients with bipolar disorder type I. However, topiramate had a more significant effect than placebo on improvement of the patients with bipolar disorder and obsessive compulsive symptoms. This combination seems to be without serious adverse effects.
  • This 4–month double–blind placebo–controlled randomized clinical trial examined the efficacy and safety of augmentation with topiramat for treating the patients with bipolar disorder, manic phase type–I, and obsessive compulsive disorder symptoms.
  • Both groups received lithium+olanzapine+clonazepam.
  • However, one group received topiramate and the other group placebo as adjuvant medications.
  • Yale Brown obsessive compulsive behavior scale was used to assess the outcome.
  • Adverse effects were also recorded.

  • A total of 32 patients completed this trial.
  • The mean score decreased from 24.2(4.8) to 17.6(8.7) in the topiramate group (P<0 data-blogger-escaped-.003="" data-blogger-escaped-20.9="" data-blogger-escaped-9.6="" data-blogger-escaped-and="" data-blogger-escaped-during="" data-blogger-escaped-from="" data-blogger-escaped-group="" data-blogger-escaped-in="" data-blogger-escaped-li="" data-blogger-escaped-placebo="" data-blogger-escaped-the="" data-blogger-escaped-this="" data-blogger-escaped-to="" data-blogger-escaped-trial="">
  • Additionally, 9(52.9%) out of 17 patients in the topiramate group and 2(12.5%) out of 16 patients in the placebo group showed more than 34% decline in YBOC score (x2=6.0, df=1, P<0 data-blogger-escaped-.01="" data-blogger-escaped-li="">
  • No serious adverse effects were detected.

Other articles in Psychiatry

>> Click here to see the complete list

No comments:

HOME (*Revenire-Pagina la Zi)